대한골관절종양학회지 (The Journal of the Korean bone and joint tumor society)
- 제1권1호
- /
- Pages.17-22
- /
- 1995
- /
- 1226-4962(pISSN)
- /
- 2233-9841(eISSN)
Stage IIB 골육종환자에서 항암 화학요법의 종류에 따른 생존율 비교
Comparison of Survival in Stage IIB Osteosarcoma According to the Chemotherapeutic Protocols
-
Jeon, Dae-Geun
(Department of Orthopedic Surgery, Korea Cancer Center Hospital)
;
-
Lee, Soo-Yong
(Department of Orthopedic Surgery, Korea Cancer Center Hospital)
;
- Lee, Jong-Seok (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
- Kim, Tae-Wan (Department of Orthopedic Surgery, Korea Cancer Center Hospital) ;
- Chung, Dong-Hwan (Department of Orthopedic Surgery, Korea Cancer Center Hospital)
- 발행 : 1995.04.30
초록
From Sept. 1986 to Dec. 1992, seventy three cases of Enneking's stage IIB osteosarcoma of extremities, which were proved histologically, took neoadjuvant chemotherapy and completed our protocol. Their average age was 16.7 years(7 to 57). For neoadjuvant chemotherapy, 37 cases took high dose methotrexate(HDMTX)-adriamycin(ADR)-cisplatin(CDDP) regimen(HDMTX group) and 36 cases took ADR-CDDP(ADR-CDDP group). The average follow up was 17 months(2-63). According to Kaplan-Meier's plot, 5-year continuously disease free survival for whole 73 cases of neoadjuvant group was 45.2%, for HDMTX group 68.4%, for ADR-CDDP group 26.6%. There was significant stastical difference between these two groups(p<0.001), with log-rank test. There can be a different survival according to the chemotherapeutic protocols. Better results can be achieved through refined protocol and effective chemotherapeutic agents.